Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Seeman

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Synapse (New York, N.Y.)|February 24, 2007
Increased dopamine D2(High) receptors in amphetamine-sensitized rats, measured by the agonist [(3)H](+)PHNOPhilip Seeman, Patrick N McCormick, Shitij Kapur
Synapse (New York, N.Y.)|April 25, 2009
Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinilPhilip Seeman, Hong-Chang Guan, Hélène Hirbec
Synapse (New York, N.Y.)|October 29, 2011
Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesiaTerence K Y Lai, Philip Seeman, Fang Liu
The European Journal of Neuroscience|May 21, 2008
Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized ratsTakahide Shuto, Philip Seeman, Mahomi Kuroiwa, et al.
Synapse (New York, N.Y.)|June 2, 2006
Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidusPhilip Seeman, Alan Wilson, Peter Gmeiner, et al.
Parkinson'S Disease|December 16, 2014
Parkinson's disease: low-dose haloperidol increases dopamine receptor sensitivity and clinical responseCraig J Hudson, Philip Seeman, Mary V Seeman
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 15, 2012
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonismGeorges Vauquelin, Sophie Bostoen, Patrick Vanderheyden, et al.
Neurochemical Research|August 29, 2012
Quantitative proteomic analysis of human substantia nigra in Alzheimer's disease, Huntington's disease and Multiple sclerosisSheng Chen, Frances Fangjia Lu, Philip Seeman, et al.
Journal of Chemical Information and Modeling|March 15, 2018
Structural Investigation of the Dopamine-2 Receptor Agonist Bromocriptine Binding to Dimeric D2<sup>High</sup>R and D2<sup>Low</sup>R StatesRamin Ekhteiari Salmas, Philip Seeman, Matthias Stein, et al.
Synapse (New York, N.Y.)|March 26, 2010
Cocaine self-administration markedly increases dopamine D2 receptor negative cooperativity for dopamine binding: A receptor dimer-based analysisRafael Franco, Philip Seeman, Carlos Barrera, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Synapse (New York, N.Y.)|February 24, 2007
Increased dopamine D2(High) receptors in amphetamine-sensitized rats, measured by the agonist [(3)H](+)PHNOPhilip Seeman, Patrick N McCormick, Shitij Kapur
Synapse (New York, N.Y.)|April 25, 2009
Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinilPhilip Seeman, Hong-Chang Guan, Hélène Hirbec
Synapse (New York, N.Y.)|October 29, 2011
Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesiaTerence K Y Lai, Philip Seeman, Fang Liu
The European Journal of Neuroscience|May 21, 2008
Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized ratsTakahide Shuto, Philip Seeman, Mahomi Kuroiwa, et al.
Synapse (New York, N.Y.)|June 2, 2006
Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidusPhilip Seeman, Alan Wilson, Peter Gmeiner, et al.
Parkinson'S Disease|December 16, 2014
Parkinson's disease: low-dose haloperidol increases dopamine receptor sensitivity and clinical responseCraig J Hudson, Philip Seeman, Mary V Seeman
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 15, 2012
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonismGeorges Vauquelin, Sophie Bostoen, Patrick Vanderheyden, et al.
Neurochemical Research|August 29, 2012
Quantitative proteomic analysis of human substantia nigra in Alzheimer's disease, Huntington's disease and Multiple sclerosisSheng Chen, Frances Fangjia Lu, Philip Seeman, et al.
Journal of Chemical Information and Modeling|March 15, 2018
Structural Investigation of the Dopamine-2 Receptor Agonist Bromocriptine Binding to Dimeric D2<sup>High</sup>R and D2<sup>Low</sup>R StatesRamin Ekhteiari Salmas, Philip Seeman, Matthias Stein, et al.
Synapse (New York, N.Y.)|March 26, 2010
Cocaine self-administration markedly increases dopamine D2 receptor negative cooperativity for dopamine binding: A receptor dimer-based analysisRafael Franco, Philip Seeman, Carlos Barrera, et al.
Pageof 9